| Interleukin-6 receptor antagonists in critically ill patients with Covid-19–preliminary report Remap-Cap Investigators, AC Gordon, PR Mouncey, F Al-Beidh, ... Medrxiv, 2021.01. 07.21249390, 2021 | 1307 | 2021 |
| Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 RCAPI The ATTACC, ACTIV-4a NEJM 385, 790-802, 2021 | 1011* | 2021 |
| Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial DC Angus, L Derde, F Al-Beidh, D Annane, Y Arabi, A Beane, ... JAMA 324 (13), 1317-1329, 2020 | 822 | 2020 |
| Interleukin-6 receptor antagonists in critically ill patients with Covid-19 Remap-Cap Investigators New England Journal of Medicine 384 (16), 1491-1502, 2021 | 620* | 2021 |
| Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis P Domingo, I Mur, GM Mateo, M del Mar Gutierrez, V Pomar, N de Benito, ... JAMA 326 (6), 499-518, 2021 | 469 | 2021 |
| Effect of Convalescent Plasma on Organ Support–Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial LJ Estcourt, et al JAMA 326 (17), 1690-1702, 2021 | 187 | 2021 |
| Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial YM Arabi, AC Gordon, LPG Derde, AD Nichol, S Murthy, FA Beidh, ... Intensive Care Medicine 47 (8), 867-886, 2021 | 86 | 2021 |
| Effect of antiplatelet therapy on survival and organ support–free days in critically ill patients with COVID-19: a randomized clinical trial C Bradbury, P Lawler, S Stanworth, B McVerry, Z McQuilten, A Higgins, ... JAMA 327 (13), 1247-1259, 2022 | 82 | 2022 |
| Long-Term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial AM Higgins, LR Berry, E Lorenzi, S Murthy, Z McQuilten, PR Mouncey, ... JAMA 329 (1), 39-51, 2023 | 80 | 2023 |
| WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for … M Shankar-Hari, CL Vale, PJ Godolphin, D Fisher, JPT Higgins, F Spiga, ... jama 326 (6), 499-518, 2021 | 67 | 2021 |
| Bayesian forecasting of many count-valued time series LR Berry, M West Journal of Business & Economic Statistics 38 (4), 872-887, 2020 | 66 | 2020 |
| Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 the REMAP-CAP COVID-19 immune modulation therapy domain randomized clinical trial REMAP-CAP Investigators, LPG Derde, AC Gordon, PR Mouncey, ... MedRxiv, 2021.06. 18.21259133, 2021 | 59 | 2021 |
| Probabilistic forecasting of heterogeneous consumer transaction–sales time series LR Berry, P Helman, M West International Journal of Forecasting 36 (2), 552-569, 2020 | 52 | 2020 |
| Effectiveness of casirivimab-imdevimab and sotrovimab during a SARS-CoV-2 Delta variant surge: a cohort study and randomized comparative effectiveness trial DT Huang, EK McCreary, JR Bariola, TE Minnier, RJ Wadas, JA Shovel, ... JAMA Network Open 5 (7), e2220957-e2220957, 2022 | 47* | 2022 |
| Heterogeneous treatment effects of therapeutic-dose heparin in patients hospitalized for COVID-19 EC Goligher, PR Lawler, TP Jensen, V Talisa, LR Berry, E Lorenzi, ... Jama 329 (13), 1066-1077, 2023 | 32 | 2023 |
| Association of subcutaneous or intravenous administration of casirivimab and imdevimab monoclonal antibodies with clinical outcomes in adults with COVID-19 EK McCreary, JR Bariola, RJ Wadas, JA Shovel, MK Wisniewski, M Adam, ... JAMA Network Open 5 (4), e226920-e226920, 2022 | 30 | 2022 |
| Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support–free days in patients hospitalized with COVID-19: a randomized … S Florescu, D Stanciu, M Zaharia, A Kosa, D Codreanu, K Fareed, ... Jama 329 (14), 1183-1196, 2023 | 27 | 2023 |
| The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open … DT Huang, EK McCreary, JR Bariola, RJ Wadas, KE Kip, OC Marroquin, ... Trials 22 (1), 363, 2021 | 23 | 2021 |
| The comparative effectiveness of COVID-19 monoclonal antibodies: a learning health system randomized clinical trial EK McCreary, JR Bariola, TE Minnier, RJ Wadas, JA Shovel, D Albin, ... Contemporary Clinical Trials 119, 106822, 2022 | 19* | 2022 |
| Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis PJ Godolphin, DJ Fisher, LR Berry, LPG Derde, JV Diaz, AC Gordon, ... PLoS One 17 (7), e0270668, 2022 | 19 | 2022 |
